Portage Biotech

About Portage Biotech

Portage Biotech is a clinical-stage biopharmaceutical company developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to enhance durable treatment responses in cancer patients. By leveraging a diverse portfolio of drug platforms and a robust industry network, the company aims to improve patient quality of life through innovative asset combinations and strategic drug development.

```xml <problem> Despite advances in immuno-oncology, a significant percentage of cancer patients, approximately 70-80%, exhibit limited or no response to existing therapies like checkpoint inhibitors. This lack of response underscores the need for novel therapeutic approaches that can overcome resistance mechanisms and enhance treatment efficacy. </problem> <solution> Portage Biotech is developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to improve durable treatment responses and quality of life for cancer patients. The company leverages a diverse portfolio of drug platforms and a network of industry partnerships to identify and advance novel assets and asset combinations. Portage Biotech actively manages the drug development process, providing strategic guidance to advance immunotherapy assets from preclinical stages through human proof-of-concept studies. Their approach involves efficient capital management and scientific oversight, with a "fail-fast" methodology to continuously evaluate and select the most promising therapeutic candidates for advancement. </solution> <features> - Diverse portfolio of drug platforms targeting various cancer resistance pathways. - Focus on first-in-class immuno-oncology therapies. - Strategic guidance for novel immunotherapy assets from bench to clinical trials. - Efficient capital management and scientific oversight to de-risk clinical development. - "Fail-fast" approach to continuously review and select promising therapeutic candidates. </features> <target_audience> The primary target audience includes cancer patients who are unresponsive or have limited response to current immuno-oncology treatments, as well as pharmaceutical companies seeking innovative assets for oncology drug development. </target_audience> ```

What does Portage Biotech do?

Portage Biotech is a clinical-stage biopharmaceutical company developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to enhance durable treatment responses in cancer patients. By leveraging a diverse portfolio of drug platforms and a robust industry network, the company aims to improve patient quality of life through innovative asset combinations and strategic drug development.

Where is Portage Biotech located?

Portage Biotech is based in Westport, United States.

When was Portage Biotech founded?

Portage Biotech was founded in 2022.

How much funding has Portage Biotech raised?

Portage Biotech has raised 6000000.

Location
Westport, United States
Founded
2022
Funding
6000000
Employees
7 employees
Looking for specific startups?
Try our free semantic startup search

Portage Biotech

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Portage Biotech is a clinical-stage biopharmaceutical company developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to enhance durable treatment responses in cancer patients. By leveraging a diverse portfolio of drug platforms and a robust industry network, the company aims to improve patient quality of life through innovative asset combinations and strategic drug development.

portagebiotech.com700+
cb
Crunchbase
Founded 2022 – Westport, United States

Funding

$

Estimated Funding

$6M+

Team (5+)

No team information available. Click "Fetch founders" to run a focused founder search.

Company Description

Problem

Despite advances in immuno-oncology, a significant percentage of cancer patients, approximately 70-80%, exhibit limited or no response to existing therapies like checkpoint inhibitors. This lack of response underscores the need for novel therapeutic approaches that can overcome resistance mechanisms and enhance treatment efficacy.

Solution

Portage Biotech is developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to improve durable treatment responses and quality of life for cancer patients. The company leverages a diverse portfolio of drug platforms and a network of industry partnerships to identify and advance novel assets and asset combinations. Portage Biotech actively manages the drug development process, providing strategic guidance to advance immunotherapy assets from preclinical stages through human proof-of-concept studies. Their approach involves efficient capital management and scientific oversight, with a "fail-fast" methodology to continuously evaluate and select the most promising therapeutic candidates for advancement.

Features

Diverse portfolio of drug platforms targeting various cancer resistance pathways.

Focus on first-in-class immuno-oncology therapies.

Strategic guidance for novel immunotherapy assets from bench to clinical trials.

Efficient capital management and scientific oversight to de-risk clinical development.

"Fail-fast" approach to continuously review and select promising therapeutic candidates.

Target Audience

The primary target audience includes cancer patients who are unresponsive or have limited response to current immuno-oncology treatments, as well as pharmaceutical companies seeking innovative assets for oncology drug development.